 Wound Care Biologics Market Insights, Competitive Landscape, and Market Forecast - 2033
The global wound care biologics market is steadily evolving as healthcare providers increasingly prioritize advanced treatment solutions for complex wounds. Biologics, derived from natural tissues ... もっと見る
※当ページの内容はウェブ更新時の情報です。
SummaryThe global wound care biologics market is steadily evolving as healthcare providers increasingly prioritize advanced treatment solutions for complex wounds. Biologics, derived from natural tissues and bioengineered materials, are transforming traditional wound management by promoting faster healing, reducing complications, and improving patient outcomes. These innovative therapies are gaining widespread adoption across hospitals, ambulatory centers, and specialized wound clinics as the burden of chronic wounds continues to rise worldwide.Market insights reveal that the wound care biologics market is expected to reach USD 2.3 billion in 2026 and grow to USD 3.3 billion by 2033, registering a compound annual growth rate (CAGR) of 5.30% over the forecast period. This growth reflects the increasing reliance on advanced wound care technologies to address conditions that are often resistant to conventional treatments. The demand for biologics is particularly strong in cases involving chronic and non-healing wounds, where regenerative therapies offer superior clinical outcomes. A key factor driving market expansion is the rising prevalence of chronic diseases such as diabetes, which significantly contributes to the incidence of wounds like diabetic foot ulcers. As global healthcare systems continue to grapple with lifestyle-related conditions, the need for effective wound care solutions is becoming more urgent. In addition, the aging population is more prone to wounds that heal slowly, further reinforcing the demand for biologics-based interventions. Advances in biotechnology and tissue engineering are also supporting the development of more efficient and targeted wound healing products. Another important growth driver is the shift toward minimally invasive and patient-friendly treatment options. Wound care biologics, including skin substitutes and topical formulations, help reduce the need for complex surgical procedures while enhancing recovery rates. Healthcare providers are increasingly adopting these products due to their ability to accelerate healing, lower infection risks, and shorten hospital stays. Supportive reimbursement frameworks in developed regions further encourage the use of biologics, making them more accessible to a larger patient population. The market also presents strong business opportunities for industry participants. Ongoing research and innovation are leading to the introduction of next-generation biologics with improved performance and broader applications. Companies are investing in product development, strategic partnerships, and geographic expansion to strengthen their competitive positions. Emerging economies, particularly in Asia Pacific and Latin America, are becoming key growth regions due to improving healthcare infrastructure, rising healthcare expenditure, and growing awareness about advanced wound care solutions. From a regional perspective, North America continues to dominate the wound care biologics market, supported by advanced healthcare systems, high adoption of innovative technologies, and favorable reimbursement policies. Europe also represents a significant market, driven by increasing healthcare investments and a strong focus on improving patient care. The Asia Pacific region is anticipated to experience the fastest growth, fueled by a large patient base, rising incidence of chronic diseases, and expanding access to modern medical treatments. Meanwhile, Latin America and the Middle East & Africa are gradually gaining traction as healthcare systems in these regions continue to develop. The competitive landscape of the wound care biologics market is characterized by the presence of several prominent companies actively working to enhance their product offerings and expand their market reach. These organizations are focusing on innovation, quality improvement, and strategic collaborations to maintain a strong foothold in the market. Key Players • Smith & Nephew plc • Organogenesis Inc. • MiMedx Group, Inc. • Integra LifeSciences Corporation • Convatec Group plc • Mölnlycke Health Care AB • Kerecis • Vericel Corporation • Osiris Therapeutics, Inc. • Anika Therapeutics, Inc. • Avita Medical, Inc. • 3M Company • Amnio Technology, LLC • Skye Biologics Holdings, LLC • Solsys Medical, LLC A detailed segmentation of the market highlights the diverse applications and product categories within the wound care biologics space, offering valuable insights into growth opportunities and demand patterns across different segments. Segmentation By Product • Biological Skin Substitutes o Human Donor Tissue-derived Products o Acellular Animal-derived Products o Biosynthetic Products • Topical Agents By Wound Type • Ulcers o Diabetic Foot Ulcers o Venous Ulcers o Pressure Ulcers o Other Ulcers • Surgical & Traumatic Wounds • Burns By End User • Hospitals • Ambulatory Surgery Centers • Burn Care Centers & Wound Clinics By Region • North America • Europe • Asia Pacific • Latin America • Middle East & Africa Table of Contents1. Executive Summary1.1. Global Wound Care Biologics Market Snapshot 1.2. Future Projections 1.3. Key Market Trends 1.4. Regional Snapshot, by Value, 2026 1.5. Analyst Recommendations 2. Market Overview 2.1. Market Definitions and Segmentations 2.2. Market Dynamics 2.2.1. Drivers 2.2.2. Restraints 2.2.3. Market Opportunities 2.3. Value Chain Analysis 2.4. COVID-19 Impact Analysis 2.5. Porter's Five Forces Analysis 2.6. Impact of Russia-Ukraine Conflict 2.7. PESTLE Analysis 2.8. Regulatory Analysis 2.9. Price Trend Analysis 2.9.1. Current Prices and Future Projections, 2025-2033 2.9.2. Price Impact Factors 3. Global Wound Care Biologics Market Outlook, 2020-2033 3.1. Global Wound Care Biologics Market Outlook, by Product, Value (US$ Bn), 2020-2033 3.1.1. Biological Skin Substitutes 3.1.1.1. Human Donor Tissue-derived Products 3.1.1.2. Acellular Animal-derived Products 3.1.1.3. Biosynthetic Products 3.1.2. Topical Agents 3.2. Global Wound Care Biologics Market Outlook, by Wound Type, Value (US$ Bn), 2020-2033 3.2.1. Ulcers 3.2.1.1. Diabetic Foot Ulcers 3.2.1.2. Venous Ulcers 3.2.1.3. Pressure Ulcers 3.2.1.4. Other Ulcers 3.2.2. Surgical & Traumatic Wounds 3.2.3. Burns 3.3. Global Wound Care Biologics Market Outlook, by End User, Value (US$ Bn), 2020-2033 3.3.1. Hospitals 3.3.2. Ambulatory Surgery Centers 3.3.3. Burn Care Centers & Wound Clinics 3.4. Global Wound Care Biologics Market Outlook, by Region, Value (US$ Bn), 2020-2033 3.4.1. North America 3.4.2. Europe 3.4.3. Asia Pacific 3.4.4. Latin America 3.4.5. Middle East & Africa 4. North America Wound Care Biologics Market Outlook, 2020-2033 4.1. North America Wound Care Biologics Market Outlook, by Product, Value (US$ Bn), 2020-2033 4.1.1. Biological Skin Substitutes 4.1.1.1. Human Donor Tissue-derived Products 4.1.1.2. Acellular Animal-derived Products 4.1.1.3. Biosynthetic Products 4.1.2. Topical Agents 4.2. North America Wound Care Biologics Market Outlook, by Wound Type, Value (US$ Bn), 2020-2033 4.2.1. Ulcers 4.2.1.1. Diabetic Foot Ulcers 4.2.1.2. Venous Ulcers 4.2.1.3. Pressure Ulcers 4.2.1.4. Other Ulcers 4.2.2. Surgical & Traumatic Wounds 4.2.3. Burns 4.3. North America Wound Care Biologics Market Outlook, by End User, Value (US$ Bn), 2020-2033 4.3.1. Hospitals 4.3.2. Ambulatory Surgery Centers 4.3.3. Burn Care Centers & Wound Clinics 4.4. North America Wound Care Biologics Market Outlook, by Country, Value (US$ Bn), 2020-2033 4.4.1. U.S. Wound Care Biologics Market Outlook, by Product, 2020-2033 4.4.2. U.S. Wound Care Biologics Market Outlook, by Wound Type, 2020-2033 4.4.3. U.S. Wound Care Biologics Market Outlook, by End User, 2020-2033 4.4.4. Canada Wound Care Biologics Market Outlook, by Product, 2020-2033 4.4.5. Canada Wound Care Biologics Market Outlook, by Wound Type, 2020-2033 4.4.6. Canada Wound Care Biologics Market Outlook, by End User, 2020-2033 4.5. BPS Analysis/Market Attractiveness Analysis 5. Europe Wound Care Biologics Market Outlook, 2020-2033 5.1. Europe Wound Care Biologics Market Outlook, by Product, Value (US$ Bn), 2020-2033 5.1.1. Biological Skin Substitutes 5.1.1.1. Human Donor Tissue-derived Products 5.1.1.2. Acellular Animal-derived Products 5.1.1.3. Biosynthetic Products 5.1.2. Topical Agents 5.2. Europe Wound Care Biologics Market Outlook, by Wound Type, Value (US$ Bn), 2020-2033 5.2.1. Ulcers 5.2.1.1. Diabetic Foot Ulcers 5.2.1.2. Venous Ulcers 5.2.1.3. Pressure Ulcers 5.2.1.4. Other Ulcers 5.2.2. Surgical & Traumatic Wounds 5.2.3. Burns 5.3. Europe Wound Care Biologics Market Outlook, by End User, Value (US$ Bn), 2020-2033 5.3.1. Hospitals 5.3.2. Ambulatory Surgery Centers 5.3.3. Burn Care Centers & Wound Clinics 5.4. Europe Wound Care Biologics Market Outlook, by Country, Value (US$ Bn), 2020-2033 5.4.1. Germany Wound Care Biologics Market Outlook, by Product, 2020-2033 5.4.2. Germany Wound Care Biologics Market Outlook, by Wound Type, 2020-2033 5.4.3. Germany Wound Care Biologics Market Outlook, by End User, 2020-2033 5.4.4. Italy Wound Care Biologics Market Outlook, by Product, 2020-2033 5.4.5. Italy Wound Care Biologics Market Outlook, by Wound Type, 2020-2033 5.4.6. Italy Wound Care Biologics Market Outlook, by End User, 2020-2033 5.4.7. France Wound Care Biologics Market Outlook, by Product, 2020-2033 5.4.8. France Wound Care Biologics Market Outlook, by Wound Type, 2020-2033 5.4.9. France Wound Care Biologics Market Outlook, by End User, 2020-2033 5.4.10. U.K. Wound Care Biologics Market Outlook, by Product, 2020-2033 5.4.11. U.K. Wound Care Biologics Market Outlook, by Wound Type, 2020-2033 5.4.12. U.K. Wound Care Biologics Market Outlook, by End User, 2020-2033 5.4.13. Spain Wound Care Biologics Market Outlook, by Product, 2020-2033 5.4.14. Spain Wound Care Biologics Market Outlook, by Wound Type, 2020-2033 5.4.15. Spain Wound Care Biologics Market Outlook, by End User, 2020-2033 5.4.16. Russia Wound Care Biologics Market Outlook, by Product, 2020-2033 5.4.17. Russia Wound Care Biologics Market Outlook, by Wound Type, 2020-2033 5.4.18. Russia Wound Care Biologics Market Outlook, by End User, 2020-2033 5.4.19. Rest of Europe Wound Care Biologics Market Outlook, by Product, 2020-2033 5.4.20. Rest of Europe Wound Care Biologics Market Outlook, by Wound Type, 2020-2033 5.4.21. Rest of Europe Wound Care Biologics Market Outlook, by End User, 2020-2033 5.5. BPS Analysis/Market Attractiveness Analysis 6. Asia Pacific Wound Care Biologics Market Outlook, 2020-2033 6.1. Asia Pacific Wound Care Biologics Market Outlook, by Product, Value (US$ Bn), 2020-2033 6.1.1. Biological Skin Substitutes 6.1.1.1. Human Donor Tissue-derived Products 6.1.1.2. Acellular Animal-derived Products 6.1.1.3. Biosynthetic Products 6.1.2. Topical Agents 6.2. Asia Pacific Wound Care Biologics Market Outlook, by Wound Type, Value (US$ Bn), 2020-2033 6.2.1. Ulcers 6.2.1.1. Diabetic Foot Ulcers 6.2.1.2. Venous Ulcers 6.2.1.3. Pressure Ulcers 6.2.1.4. Other Ulcers 6.2.2. Surgical & Traumatic Wounds 6.2.3. Burns 6.3. Asia Pacific Wound Care Biologics Market Outlook, by End User, Value (US$ Bn), 2020-2033 6.3.1. Hospitals 6.3.2. Ambulatory Surgery Centers 6.3.3. Burn Care Centers & Wound Clinics 6.4. Asia Pacific Wound Care Biologics Market Outlook, by Country, Value (US$ Bn), 2020-2033 6.4.1. China Wound Care Biologics Market Outlook, by Product, 2020-2033 6.4.2. China Wound Care Biologics Market Outlook, by Wound Type, 2020-2033 6.4.3. China Wound Care Biologics Market Outlook, by End User, 2020-2033 6.4.4. Japan Wound Care Biologics Market Outlook, by Product, 2020-2033 6.4.5. Japan Wound Care Biologics Market Outlook, by Wound Type, 2020-2033 6.4.6. Japan Wound Care Biologics Market Outlook, by End User, 2020-2033 6.4.7. South Korea Wound Care Biologics Market Outlook, by Product, 2020-2033 6.4.8. South Korea Wound Care Biologics Market Outlook, by Wound Type, 2020-2033 6.4.9. South Korea Wound Care Biologics Market Outlook, by End User, 2020-2033 6.4.10. India Wound Care Biologics Market Outlook, by Product, 2020-2033 6.4.11. India Wound Care Biologics Market Outlook, by Wound Type, 2020-2033 6.4.12. India Wound Care Biologics Market Outlook, by End User, 2020-2033 6.4.13. Southeast Asia Wound Care Biologics Market Outlook, by Product, 2020-2033 6.4.14. Southeast Asia Wound Care Biologics Market Outlook, by Wound Type, 2020-2033 6.4.15. Southeast Asia Wound Care Biologics Market Outlook, by End User, 2020-2033 6.4.16. Rest of SAO Wound Care Biologics Market Outlook, by Product, 2020-2033 6.4.17. Rest of SAO Wound Care Biologics Market Outlook, by Wound Type, 2020-2033 6.4.18. Rest of SAO Wound Care Biologics Market Outlook, by End User, 2020-2033 6.5. BPS Analysis/Market Attractiveness Analysis 7. Latin America Wound Care Biologics Market Outlook, 2020-2033 7.1. Latin America Wound Care Biologics Market Outlook, by Product, Value (US$ Bn), 2020-2033 7.1.1. Biological Skin Substitutes 7.1.1.1. Human Donor Tissue-derived Products 7.1.1.2. Acellular Animal-derived Products 7.1.1.3. Biosynthetic Products 7.1.2. Topical Agents 7.2. Latin America Wound Care Biologics Market Outlook, by Wound Type, Value (US$ Bn), 2020-2033 7.2.1. Ulcers 7.2.1.1. Diabetic Foot Ulcers 7.2.1.2. Venous Ulcers 7.2.1.3. Pressure Ulcers 7.2.1.4. Other Ulcers 7.2.2. Surgical & Traumatic Wounds 7.2.3. Burns 7.3. Latin America Wound Care Biologics Market Outlook, by End User, Value (US$ Bn), 2020-2033 7.3.1. Hospitals 7.3.2. Ambulatory Surgery Centers 7.3.3. Burn Care Centers & Wound Clinics 7.4. Latin America Wound Care Biologics Market Outlook, by Country, Value (US$ Bn), 2020-2033 7.4.1. Brazil Wound Care Biologics Market Outlook, by Product, 2020-2033 7.4.2. Brazil Wound Care Biologics Market Outlook, by Wound Type, 2020-2033 7.4.3. Brazil Wound Care Biologics Market Outlook, by End User, 2020-2033 7.4.4. Mexico Wound Care Biologics Market Outlook, by Product, 2020-2033 7.4.5. Mexico Wound Care Biologics Market Outlook, by Wound Type, 2020-2033 7.4.6. Mexico Wound Care Biologics Market Outlook, by End User, 2020-2033 7.4.7. Argentina Wound Care Biologics Market Outlook, by Product, 2020-2033 7.4.8. Argentina Wound Care Biologics Market Outlook, by Wound Type, 2020-2033 7.4.9. Argentina Wound Care Biologics Market Outlook, by End User, 2020-2033 7.4.10. Rest of LATAM Wound Care Biologics Market Outlook, by Product, 2020-2033 7.4.11. Rest of LATAM Wound Care Biologics Market Outlook, by Wound Type, 2020-2033 7.4.12. Rest of LATAM Wound Care Biologics Market Outlook, by End User, 2020-2033 7.5. BPS Analysis/Market Attractiveness Analysis 8. Middle East & Africa Wound Care Biologics Market Outlook, 2020-2033 8.1. Middle East & Africa Wound Care Biologics Market Outlook, by Product, Value (US$ Bn), 2020-2033 8.1.1. Biological Skin Substitutes 8.1.1.1. Human Donor Tissue-derived Products 8.1.1.2. Acellular Animal-derived Products 8.1.1.3. Biosynthetic Products 8.1.2. Topical Agents 8.2. Middle East & Africa Wound Care Biologics Market Outlook, by Wound Type, Value (US$ Bn), 2020-2033 8.2.1. Ulcers 8.2.1.1. Diabetic Foot Ulcers 8.2.1.2. Venous Ulcers 8.2.1.3. Pressure Ulcers 8.2.1.4. Other Ulcers 8.2.2. Surgical & Traumatic Wounds 8.2.3. Burns 8.3. Middle East & Africa Wound Care Biologics Market Outlook, by End User, Value (US$ Bn), 2020-2033 8.3.1. Hospitals 8.3.2. Ambulatory Surgery Centers 8.3.3. Burn Care Centers & Wound Clinics 8.4. Middle East & Africa Wound Care Biologics Market Outlook, by Country, Value (US$ Bn), 2020-2033 8.4.1. GCC Wound Care Biologics Market Outlook, by Product, 2020-2033 8.4.2. GCC Wound Care Biologics Market Outlook, by Wound Type, 2020-2033 8.4.3. GCC Wound Care Biologics Market Outlook, by End User, 2020-2033 8.4.4. South Africa Wound Care Biologics Market Outlook, by Product, 2020-2033 8.4.5. South Africa Wound Care Biologics Market Outlook, by Wound Type, 2020-2033 8.4.6. South Africa Wound Care Biologics Market Outlook, by End User, 2020-2033 8.4.7. Egypt Wound Care Biologics Market Outlook, by Product, 2020-2033 8.4.8. Egypt Wound Care Biologics Market Outlook, by Wound Type, 2020-2033 8.4.9. Egypt Wound Care Biologics Market Outlook, by End User, 2020-2033 8.4.10. Nigeria Wound Care Biologics Market Outlook, by Product, 2020-2033 8.4.11. Nigeria Wound Care Biologics Market Outlook, by Wound Type, 2020-2033 8.4.12. Nigeria Wound Care Biologics Market Outlook, by End User, 2020-2033 8.4.13. Rest of Middle East Wound Care Biologics Market Outlook, by Product, 2020-2033 8.4.14. Rest of Middle East Wound Care Biologics Market Outlook, by Wound Type, 2020-2033 8.4.15. Rest of Middle East Wound Care Biologics Market Outlook, by End User, 2020-2033 8.5. BPS Analysis/Market Attractiveness Analysis 9. Competitive Landscape 9.1. Company Vs Segment Heatmap 9.2. Company Market Share Analysis, 2025 9.3. Competitive Dashboard 9.4. Company Profiles 9.4.1. Smith & Nephew plc 9.4.1.1. Company Overview 9.4.1.2. Product Portfolio 9.4.1.3. Financial Overview 9.4.1.4. Business Strategies and Developments 9.4.2. Organogenesis Inc. 9.4.3. MiMedx Group, Inc. 9.4.4. Integra LifeSciences Corporation 9.4.5. Convatec Group plc 9.4.6. Mölnlycke Health Care AB 9.4.7. Kerecis 9.4.8. Vericel Corporation 9.4.9. Osiris Therapeutics, Inc. 9.4.10. Anika Therapeutics, Inc. 10. Appendix 10.1. Research Methodology 10.2. Report Assumptions 10.3. Acronyms and Abbreviations
ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。本レポートと同分野（医療IT）の最新刊レポート
Fairfield Market Research社の ヘルスケアIT分野 での最新刊レポート
本レポートと同じKEY WORD（wound care）の最新刊レポートよくあるご質問Fairfield Market Research社はどのような調査会社ですか?Fairfield Market Researchでは、最新かつ最も関連性の高い市場データと洞察に満ちた詳細なレポートを発行しています。広範囲にわたり、業界動向や市場ベースのデータを含んでおり、顧客が... もっと見る 調査レポートの納品までの日数はどの程度ですか?在庫のあるものは速納となりますが、平均的には 3-４日と見て下さい。
注文の手続きはどのようになっていますか?1)お客様からの御問い合わせをいただきます。
お支払方法の方法はどのようになっていますか?納品と同時にデータリソース社よりお客様へ請求書（必要に応じて納品書も）を発送いたします。
データリソース社はどのような会社ですか?当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
|
|
